Content
All Posts > Content under Pharma/Biotech
Insys: Will The Drug Pipeline Drive Growth?
Article By:
Shock Exchange
Read
Monday, March 12, 2018 5:11 AM EDT
INSY's Q4 revenue declined over 40% Y/Y, but was up 3% sequentially. Revenue declines appear to have subsided. Its $163MM of cash and investments could support the company until its drug pipeline kicks in.
3 ‘Strong Buy’ Biotechs That Can Double In 2018
Investors Try On AI-based Drug Discovery With BioXcel
Article By:
IPO Candy
Read
Sunday, March 11, 2018 11:40 AM EDT
Last week BioXcel Therapeutics (Nasdaq: BTAI) went public at $11. BioXcel's approach to drug development is taking the large inventory of known molecules and coming up with new and different ways to apply them alone or in different combinations.
In this article: BTAI
Week In Review: China Pharma Deals Top $1.5 Billion For Week
Article By:
ChinaBio® Today
Read
Saturday, March 10, 2018 6:04 PM EDT
Tianjin Tasly Pharma (SHA: 600535) is in talks to IPO its biopharma division in Hong Kong later this year with the goal of raising $1 billion. If it happens, the IPO will probably be Hong Kong's largest biopharma IPO this year.
In this article: HCM
Regeneron, Sanofi Say Odyssey Outcomes Trial Met Primary Endpoint
Corvus Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
Article By:
NASDAQ GlobeNewswire
Read
Thursday, March 8, 2018 9:20 PM EDT
Corvus Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 7,058,824 shares of its common stock at a price to the public of $8.50 per share.
In this article: CRVS
Global Blood Therapeutics Announces Proposed Public Offering Of Common Stock
Article By:
NASDAQ GlobeNewswire
Read
Thursday, March 8, 2018 5:40 PM EDT
Global Blood Therapeutics, Inc. today announced a registered offering of 3,500,000 shares of its common stock.
In this article: GBT
5 Canadian Cannabis Updates That Impacted Shares
Article By:
Technical420
Read
Thursday, March 8, 2018 2:06 PM EDT
The Canadian cannabis sector recently came off its highs and investors are closely monitoring the recent pullback. Prior to this weakness, Canadian cannabis stocks were in rally mode and we remain bullish on these moves.
Humana, WellCare Dip After Cigna Agrees To Buy Express Scripts
Bear Of The Day: Endo International (ENDP)
Article By:
Zacks Investment Research
Read
Thursday, March 8, 2018 1:46 PM EDT
Shares of Endo are down about 6.7% so far this year, and have sunk well over 36% in the past one year.
ADMA Biologics: Almost Ready To Run Between The Toes Of Giants
Article By:
Simon Daly
Read
Tuesday, March 6, 2018 10:27 PM EDT
ADMA’s lead product candidate has positive data, positioned for high unmet medical need. The burden of lifting regulatory hold is lower than might be perceived by investors at present.
In this article: ADMA
Biotechs Buffeted By Macro News But Should Continue To Outperform
Article By:
Rod Raynovich
Read
Tuesday, March 6, 2018 12:04 PM EDT
Biotechs outperform in 2018 having recovered most of their losses from last week’s volatility caused by dire tariff talk and higher interest rates, raising concerns about the impact on global growth.
Innovate Biopharmaceuticals: Why Is This Stock Flying?
Article By:
Quad 7 Capital
Read
Tuesday, March 6, 2018 9:17 AM EDT
Innovate Biopharmaceuticals has risen heavily in the last two trading sessions seemingly on no news. The company recently underwent a reverse recapitalization, but more importantly, has a leading drug candidature.
Dermira Stock Is Tanking: Here Is Why
Article By:
Quad 7 Capital
Read
Monday, March 5, 2018 2:45 PM EDT
Dermira stock is down heavily today following posted results of to phase 3 pivotal clinical trials for its leading drug candidates for moderate-to-severe acne vulgaris. None of the co-primary endpoint results were statistically significant.
In this article: DERM
5 Top Stocks To Survive A Trade War
Week In Review: Grail Plans $500 Million Hong Kong IPO For Cancer Diagnostics
Article By:
ChinaBio® Today
Read
Saturday, March 3, 2018 5:10 PM EDT
Grail, a US spinout from Illumina that is developing blood-based cancer detection tests, is considering a $500 million Hong Kong IPO. Last year, Grail completed a $900 million Series B fundraising, the largest ever.
In this article: ILMN